CSL has pledged more than $355 million to co-develop lixudebart with private Swiss group Alentis Therapeutics, targeting rare kidney and liver disorders.
Rare disease focus and early trial data
The candidate works by reducing inflammation and fibrosis. It is now being tested in a phase II study called RENAL F02, which enrolls patients with ANCA-associated vasculitis and rapidly progressive glomerulonephritis (AAV-RPGN).
AAV-RPGN is an autoimmune condition that can lead to irreversible kidney damage and end-stage renal disease. Epidemiologists estimate it affects roughly 200 to 400 people per million worldwide.
CSL’s head of research and development, Dr Bill Mezzanotte, said the early readout from the first 40 of 80 participants looks encouraging. “We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease,” he told reporters.
He added that clinical markers are moving in a positive direction and that the tolerability profile is very good, giving the team confidence in the candidate’s safety.
Mezzanotte cautioned that “all things are still an experiment until they’re final, so I’ll never declare victory too soon.”
Read Also: UBS Raises Iron Ore Forecast to $93 Highlights Junior Miners
Expansion plans and financial structure
The partnership also aims to test lixudebart in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC), two chronic diseases with limited treatment options.
Under the agreement, CSL will fund the completion of the RENAL trial, which is currently about two-thirds recruited, and will cover phase II studies for FSGS and PSC. If the drug reaches the market, CSL could receive up to $1.2 billion in commercial milestones, sharing global profits on a 55%-45% split with Alentis.
Earlier this year, the European Medicines Agency recommended withdrawing marketing authorisation for Tavneos, CSL’s previously licensed therapy for severe ANCA-associated vasculitis. The European Commission formally revoked the authorisation in August, ending a product that generated about $145 million in revenue for CSL in the year to June 2026.
Should lixudebart prove effective, it could fill the gap left by Tavneos and provide a new source of earnings for the company.
Dimerix advances in FSGS trials while CSL plans follow-on phase III study
Dimerix (ASX:DXB) has entered phase III testing for focal segmental glomerulosclerosis, employing a mechanism different from CSL’s candidate. The disease remains a rare chronic kidney disorder with few therapeutic options.
Primary sclerosing cholangitis, the liver condition targeted alongside FSGS, currently has no approved therapy. CSL’s agreement includes financing a subsequent phase III trial that would launch if the RENAL study meets its primary endpoints.
The Dimerix program targets a separate biological pathway, offering a potential complementary approach to ongoing efforts to reduce kidney inflammation and fibrosis.
Read Also: ASX small caps have mixed week
Regulatory moves by Optiscan
Optiscan submitted a 510(k) clearance request to the FDA for its digital pathology platform, InForm. The filing follows a similar submission for the intra-operative imaging system InVue.
Both devices are positioned to become the firm’s first tools cleared for human use. InVue, unveiled in mid-2024, delivers cellular-level visualization directly within the operating theatre, eliminating the need for conventional tissue biopsies.
Regulators will assess InVue under the same predicate pathway as InForm. Successful clearance could allow surgeons to evaluate margins in real time, potentially reducing repeat procedures.
Optiscan targets the oncology market as its initial focus. The company estimates the U.S. cancer surgery market at 1.27 million patients a year and a $4.8 billion annual opportunity.
InForm aims to digitize conventional slide-based analysis, offering slide-free imaging at the point of care.
Aroa’s Symphony shows promise in diabetic foot ulcers
Aroa Biosurgery reported outcomes from a randomized, controlled trial evaluating its extracellular matrix scaffold, Symphony, in addition to standard wound care.
Read Also: Australian firms set to hand out $40bn dividends
The study enrolled 143 participants with Wagner grade one or two diabetic foot ulcers across ten U.S. sites. Patients received either Symphony plus usual care or standard care alone.
Results indicated that 55% of ulcers treated with Symphony achieved complete closure within 12 weeks, compared with 35% in the control group.
Average time to full closure was 65.4 days for the Symphony cohort, while the standard-care group required 73.2 days.
Symphony, derived from biologic sheep forestomach tissue, received FDA approval in 2020 and has since secured reimbursement pathways.
Aroa says the trial’s findings provide robust clinical evidence supporting Symphony’s effectiveness and are expected to support product differentiation, clinical adoption and evolving U.S. reimbursement requirements.
Aroa CEO Brian Ward says the study provided clear statistically significant results.
